リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease

Ikeda, Suguru Sugihara, Takaaki Hoshino, Yoshiki Matsuki, Yukako Nagahara, Takakazu Okano, Jun-ichi Kitao, Sonoko Fujioka, Youhei Yamamoto, Kazuhiro Isomoto, Hajime 鳥取大学 DOI:10.33160/yam.2020.08.009

2020.08.20

概要

[Background] Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome, which can progress to liver cirrhosis. Standard medication has not been established. Pemafibrate is a selective peroxisome proliferatoractivated receptor (PPAR) α modulator. We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD. [Methods] We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27?81 years). They were all proven to have fatty liver through imaging and had little or no history of drinking (ethanol consumption of < 20 g/day for women and < 30 g/day for men). They were administered pemafibrate from October 2018 to June 2020. [Results] After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06). Serum high-density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol levels did not change. ALT was significantly decreased (-47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01). The values of serum GGT significantly decreased (-48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change. [Conclusion] Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K,

Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American

Association for the Study of Liver Diseases. Hepatology.

2018;67:328-57. DOI: 10.1002/hep.29367, PMID: 28714183

2 Liu CJ. Prevalence and risk factors for non-alcoholic

fatty liver disease in Asian people who are not obese. J

Gastroenterol Hepatol. 2012;27:1555-60. DOI: 10.1111/j.14401746.2012.07222.x, PMID: 22741595

3 Sumida Y, Yoneda M. Current and future pharmacological

therapies for NAFLD/NASH. J Gastroenterol. 2018;53:36276. DOI: 10.1007/s00535-017-1415-1, PMID: 29247356

4 Berger J, Moller DE. The mechanisms of action of PPARs.

Annu Rev Med. 2002;53:409-35. DOI: 10.1146/annurev.

med.53.082901.104018, PMID: 11818483

5 Issemann I, Green S. Activation of a member of the steroid

hormone receptor superfamily by peroxisome proliferators.

Nature. 1990;347:645-50. DOI: 10.1038/347645a0, PMID:

2129546

6 Abdelmegeed MA, Moon KH, Hardwick JP, Gonzalez FJ,

Song BJ. Role of peroxisome proliferator-activated receptor-α

in fasting-mediated oxidative stress. Free Radic Biol Med.

2009;47:767-78. DOI: 10.1016/j.freeradbiomed.2009.06.017,

PMID: 19539749

196

© 2020 Tottori University Medical Press

Pemafibrate decreased values of LFTs and APRI in NAFLD

19 Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress

in the pathogenesis of nonalcoholic fatty liver disease.

Free Radic Biol Med. 2020;152:116-41. DOI: 10.1016/

j.freeradbiomed.2020.02.025, PMID: 32156524

20 Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current

status of imaging in nonalcoholic fatty liver disease. World

J Hepatol. 2018;10:530-42. DOI: 10.4254/wjh.v10.i8.530,

PMID: 30190781

21 Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A,

Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate

marker of fibrosis in HCV infection. comparison with liver

biopsy and fibrotest. Hepatology. 2007;46:32-6. DOI: 10.1002/

hep.21669, PMID: 17567829

22 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP.

Simple non-invasive fibrosis scoring systems can reliably

exclude advanced fibrosis in patients with non-alcoholic

fatty liver disease. Gut. 2010;59:1265-9. DOI: 10.1136/

gut.2010.216077, PMID: 20801772

23 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ,

Sanyal AJ; Nash Clinical Research Network. Comparison of

noninvasive markers of fibrosis in patients with nonalcoholic

fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:110412. DOI: 10.1016/j.cgh.2009.05.033, PMID: 19523535

24 Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero

JA, Conjeevaram HS, et al. A simple noninvasive index

can predict both significant fibrosis and cirrhosis in patients

with chronic hepatitis C. Hepatology. 2003;38:518-26. DOI:

10.1053/jhep.2003.50346, PMID: 12883497

25 Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K,

van Rensburg C, et al. APRI: a simple bedside marker for

advanced fibrosis that can avoid liver biopsy in patients

with NAFLD/NASH. S Afr Med J. 2011;101:477-80. PMID:

21920102

26 Fernández-Miranda C, Pérez-Carreras M, Colina F,

López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot

trial of fenofibrate for the treatment of non-alcoholic fatty

liver disease. Dig Liver Dis. 2008;40:200-5. DOI: 10.1016/

j.dld.2007.10.002, PMID: 18261709

27 Gand hi N, Lenton R, Bhar tia M, Abbas A, Raju J,

Ramachandran S. Effect of fibrate treatment on liver function

tests in patients with the metabolic syndrome. Springerplus.

2014;3:14. DOI: 10.1186/2193-1801-3-14, PMID: 24455467

28 Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARα modulator, pemafibrate, in

dyslipidemia and metabolic diseases. J Atheroscler Thromb.

2019;26:389-402. DOI: 10.5551/jat.48918, PMID: 30930344

29 Polyzos S, Slavakis A, Koumerkeridis G, Katsinelos P,

Kountouras J. Noninvasive Liver Fibrosis Tests in Patients

with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. Horm Metab Res. 2019;51:134-40. DOI: 10.1055/

a-0713-1330, PMID: 30273934

30 Luyendyk J, Lisman T. Platelets as Modulators of Liver Diseases. Semin Thromb Hemost. 2018;44:114-25. DOI: 10.1055/

s-0037-1604091, PMID: 28898899

31 Diggs LP, Greten TF. The effects of platelet accumulation

in fatty liver disease. Nat Rev Gastroenterol Hepatol.

2019;16:393-4. DOI: 10.1038/s41575-019-0160-8, PMID:

31114057

32 Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease.

Hepat Med. 2016;8:39-50. PMID: 27186144

33 Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer

and regeneration. World J Gastroenterol. 2017;23:3228-39.

DOI: 10.3748/wjg.v23.i18.3228, PMID: 28566882

34 Wang L, Wang B, You H, Wu X, Zhou J, Ou X, et al.

Platelets’ increase is associated with improvement of liver

fibrosis in entecavir-treated chronic hepatitis B patients with

significant liver fibrosis. Hepatol Int. 2018;12:237-43. DOI:

10.1007/s12072-018-9864-z, PMID: 29700765

35 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in nonalcoholic fatty liver disease: A systematic review and metaanalysis. Biomed Rep. 2013;1:57-64. DOI: 10.3892/br.2012.18,

PMID: 24648894

36 Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty

liver in type 2 diabetes: A common comorbidity associated

with severe complications. Diabetes Metab. 2019;45:213-23.

DOI: 10.1016/j.diabet.2019.01.008, PMID: 30708071

197

© 2020 Tottori University Medical Press

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る